Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations

This publication has 18 references indexed in Scilit:

• Outcomes in Patients with Acute Non–Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy
  New England Journal of Medicine, 1998
• Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
  JAMA, 1998
• Effect of Pravastatin on Angiographic Restenosis After Coronary Balloon Angioplasty fn1fn1This study was supported by a grant from Bristol Myers Squibb Laboratories, Paris.
  JACC, 1997
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
  New England Journal of Medicine, 1996
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995
• Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients
  The American Journal of Cardiology, 1995
• Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels
  Circulation, 1995
• Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
  Circulation, 1994
• Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS)
  Annals of Internal Medicine, 1993
• Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)
  The American Journal of Cardiology, 1991